Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML): Results of a phase I dose-escalation and expansion study. Stein, E. M., Dinardo, C., Pollyea, D., Fathi, A., Roboz, G. J., Altman, J. K., Stone, R. M., Flinn, I., Kantarjian, H. M., Collins, R., Patel, M. R., Stein, A., Sekeres, M. A., Swords, R. T., Medeiros, B. C., Knight, R. D., Agresta, S. V., De Botton, S., Tallman, M. S. AMER SOC CLINICAL ONCOLOGY. 2017

View details for DOI 10.1200/JCO.2017.35.15_suppl.7004

View details for Web of Science ID 000411931708034